The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Philipp M. Cromm, Craig M. Crews, Nello Mainolfi, Tim Rasmusson, Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Kevan M. Shokat, Neal Rosen, Craig M. Crews, Bogos Agianian, Evripidis Gavathiotis, Kanak Raina, Craig M. Crews, David E. Durrant, Deborah K. Morrison, Taavi K. Neklesa, James D. Winkler, Craig M. Crews, F. ChangL. S. Steelman, J. T. Lee, J. G. Shelton, P. M. Navolanic, W. L. Blalock, R. A. Franklin, J. A. McCubrey, George M. Burslem, Blake E. Smith, Ashton C. Lai, Saul Jaime-Figueroa, Daniel C. McQuaid, Daniel P. Bondeson, Momar Toure, Hanqing Dong, Yimin Qian, Jing Wang, Andrew P. Crew, John Hines, Craig M. Crews, Jaquelyn N. Sanchez, Ton Wang, Mark S. Cohen, Lindsay Shelledy, PharmD, Danielle Roman, PharmD, BCOP, Helen Davies, Graham R. Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J. Garnett, William Bottomley, Neil Davis, Ed Dicks, Rebecca Ewing, Yvonne Floyd, Kristian Gray, Sarah Hall, Rachel Hawes, Jaime Hughes, Vivian Kosmidou, Andrew Menzies, Catherine Mould, Adrian Parker, Claire Stevens, Stephen Watt, Steven Hooper, Hiran Jayatilake, Barry A. Gusterson, Colin Cooper, Janet Shipley, Darren Hargrave, Katherine Pritchard-Jones, Norman Maitland, Georgia Chenevix-Trench, Gregory J. Riggins, Darell D. Bigner, Giuseppe Palmieri, Antonio Cossu, Adrienne Flanagan, Andrew Nicholson, Judy W.C. Ho, Suet Y. Leung, Siu T. Yuen, Barbara L. Weber, Hilliard F. Seigler, Timothy L. Darrow, Hugh Paterson, Richard Wooster, Richard Wooster, Michael R. Stratton, P. Andrew Futreal, Chao Zhang, Wayne Spevak, Ying Zhang, Elizabeth A. Burton, Yan Ma, Gaston Habets, Jiazhong Zhang, Jack Lin, Todd Ewing, Bernice Matusow, Garson Tsang, Adhirai Marimuthu, Hanna Cho, Guoxian Wu, Weiru Wang, Daniel Fong, Hoa Nguyen, Songyuan Shi, Patrick Womack, Marika Nespi, Rafe Shellooe, Heidi Carias, Ben Powell, Emily Light, Laura Sanftner, Jason Walters, James Tsai, Brian L. West, Gary Visor, Hamid Rezaei, Paul S. Lin, Keith Nolop, Prabha N. Ibrahim, Peter Hirth, Gideon Bollag, Imanol Arozarena, Claudia Wellbrock, Ahmed A. Samatar, Poulikos I. Poulikakos, Zoi Karoulia, Evripidis Gavathiotis, Poulikos I. Poulikakos, Paul B. Chapman, Axel Hauschild, Caroline Robert, John B. Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Celeste Lebbe, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven J. O'Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dreno, Keith Nolop, Jiang Li, Betty Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur, Bert Vogelstein, Nickolas Papadopoulos, Victor E. Velculescu, Shibin Zhou, Luis A. Diaz, Kenneth W. Kinzler, G. W.M. Millington, Daniel P. Bondeson, Blake E. Smith, George M. Burslem, Alexandru D. Buhimschi, John Hines, Saul Jaime-Figueroa, Jing Wang, Brian D. Hamman, Alexey Ishchenko, Craig M. Crews

Research output: Contribution to journalArticlepeer-review

Abstract

Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degradation. The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degradation over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degradation leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors. Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degradation using the PROTAC technology and outline the advantages of this degradation-based approach. Burslem, Smith et al. describe the development of PROTACs capable of degrading transmembrane receptor tyrosine kinases and further highlight the advantages of degradation over inhibition in terms of potency, duration of effect, and combating compensatory signaling.
Original languageEnglish
Pages (from-to)67-77.e3
JournalCell Chemical Biology
Early online date9 Nov 2017
DOIs
Publication statusPublished - 2018

Keywords

  • CRBN
  • Cereblon
  • Cytokines
  • E3 ligase
  • EGFR
  • ERK cascade
  • HER2
  • Heterobifunctional degrader
  • MAPK kinase cascade
  • MAPK/p38
  • Oncogenes
  • PROTAC
  • PROTACs
  • Protein degradation
  • Raf inhibitors
  • Raf kinases
  • Ras pathway
  • SNIPER
  • Signal transduction
  • Small molecular weight membrane-permeable inhibito
  • Targeted protein degradation
  • Therapeutic intervention
  • Ubiquitination
  • Undruggable proteome
  • VHL
  • c-Met
  • cancer therapy
  • chemical biology
  • hydrophobic tagging
  • protein degradation
  • protein dimerisation
  • protein-protein interactions
  • proteomics
  • receptor tyrosine kinases
  • selective degradation
  • targeted degradation
  • ternary complex

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study'. Together they form a unique fingerprint.

Cite this